Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Not Applicable

Completed

Conditions: Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7
Stage II Prostate Adenocarcinoma AJCC v7
Stage III Prostate Adenocarcinoma AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2016-07-12

Last Posted Date: 2024-05-23

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 11

Registration Number: NCT02830165

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

C11 Sodium Acetate PET/CT Imaging of PCa

Conditions: Prostate Cancer

First Posted Date: 2016-07-11

Last Posted Date: 2020-07-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT02826395

Locations: 🇺🇸
200 Medical Plaza, B114, Los Angeles, California, United States

Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men

Not Applicable

Active, not recruiting

Conditions: Human Papillomavirus Infection
Anal Carcinoma
HIV Infection

Interventions: Procedure: Cytology Specimen Collection Procedure
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-06-29

Last Posted Date: 2024-07-16

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 415

Registration Number: NCT02816879

Locations: 🇺🇸
Los Angeles Gay and Lesbian Center, Los Angeles, California, United States
🇺🇸
Desert AIDS Project, Palm Springs, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

Phase 1

Completed

Conditions: Childhood Solid Neoplasm
Adult Solid Neoplasm
Metastatic Neoplasm

Interventions: Biological: Aldesleukin
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL
Biological: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine
Procedure: Positron Emission Tomography

First Posted Date: 2016-05-17

Last Posted Date: 2020-07-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT02775292

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Withdrawn

Conditions: High Grade Fallopian Tube Serous Adenocarcinoma
Primary Peritoneal High Grade Serous Adenocarcinoma
Recurrent Primary Peritoneal Carcinoma
High Grade Ovarian Serous Adenocarcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma

Interventions: Drug: Birinapant
Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2016-04-29

Last Posted Date: 2020-07-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT02756130

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

Not Applicable

Recruiting

Conditions: Recurrent Adult Soft Tissue Sarcoma

Interventions: Procedure: Conventional Surgery
Radiation: Hypofractionated Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration

First Posted Date: 2016-03-08

Last Posted Date: 2024-07-25

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 51

Registration Number: NCT02701153

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma

Conditions: Urothelial Carcinoma Ureteral Location

First Posted Date: 2016-03-07

Last Posted Date: 2017-09-14

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT02701023

Locations: 🇺🇸
UCLA, Los Angeles, California, United States

Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer

Not Applicable

Withdrawn

Conditions: Infiltrating Bladder Urothelial Carcinoma

Interventions: Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2016-02-23

Last Posted Date: 2020-07-24

Lead Sponsor: Jonsson Comprehensive Cancer Center

Registration Number: NCT02688348

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer

Early Phase 1

Completed

Conditions: Adult Hepatocellular Carcinoma
Metastatic Malignant Neoplasm in the Liver

Interventions: Radiation: Image-Guided Adaptive Radiation Therapy
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2016-02-17

Last Posted Date: 2023-02-21

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 21

Registration Number: NCT02683200

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules

Active, not recruiting

Conditions: Thyroid

Interventions: Other: ThyroSeq v.3
Other: Afirma GSC
Other: Afirma GEC
Other: ThyroSeq v.2

First Posted Date: 2016-02-12

Last Posted Date: 2024-01-05

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 328

Registration Number: NCT02681328

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy